MGX — Metagenomi, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$1.17
-$0.01 (-0.85%)
Metagenomi, Inc. Common Stock (MGX) is a biotechnology company listed on NASDAQ. It is led by Jian Irish M.B.A., Ph.D., based in 5959 Horton Street, EmeryVille, CA, United States, 94608, with about 119 employees. Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Latest reported MGX revenue for 2025-09-30 was $8.7M. Net income was -$65.3M. Revenue was up 1.7% from 2025-06-30 to 2025-09-30. MGX currently screens at market cap $44.4M.
Use this MGX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MGX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MGX SEC filings page. Lician reads the product cache first so this HTML stays unique to Metagenomi, Inc. Common Stock even when a live quote feed is slow.
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
MGX Key Statistics
Market Cap
$44.42M
Volume
124,870
Previous Close
$1.21
Day Range
$1.21 – $1.25
P/B Ratio
0.32
EPS
-$2.36
Revenue
$52.30M
Net Income
-$78.06M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+16.8%
Profit Margin
-149.3%
Employees
119
MGX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $52.30M | $44.76M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$78.06M | -$68.25M |
| EPS (Diluted) | -$2.36 | -$20.05 |
Total Assets
$324.60M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$27.39M
Operating Cash Flow
-$109.07M
Free Cash Flow
$0.00
Metagenomi, Inc. Common Stock Company Information
- CEO, President & Director
- Jian Irish M.B.A., Ph.D.
- Headquarters
- 5959 Horton Street, EmeryVille, CA, United States, 94608
- Website
- metagenomi.co
- Phone
- 510 871 4880
- IPO / Founded
- 2024-02-09
- Sector
- Healthcare
- Industry
- Biotechnology